套细胞淋巴瘤一线免疫化疗演变与生存结局
该前瞻性队列研究纳入2002至2015年新诊断套细胞淋巴瘤患者,比较2002-2009年与2010-2015年一线治疗模式变化及结局。≤65岁患者中R-Hyper-CVAD减少、Nordic方案及R-DHAP增加、R-CHOP减少而R-苯达莫司汀增加,与EFS和OS改善相关;>65岁患者R-CHOP减少、R-苯达莫司汀增加,EFS有改善趋势。
要点
- ≤65岁患者治疗模式变化与5年EFS和OS改善相关
- >65岁患者R-苯达莫司汀增加与EFS改善相关
- 真实世界证据支持MCL一线治疗模式演变改善结局
核心结论
- MCL一线治疗模式随时间演变,与≤65岁患者EFS和OS改善相关,>65岁患者EFS有改善趋势。
研究设计与样本
- 前瞻性队列研究,纳入2002年9月至2015年6月新诊断MCL患者,比较2002-2009年(Era 1)与2010-2015年(Era 2)的治疗模式及结局。
- 两组患者年龄、性别和简化MCL国际预后指数(sMIPI)评分相似。
主要发现
- ≤65岁患者中,Era 2较Era 1的R-Hyper-CVAD使用减少(16.1% vs 8.8%),Nordic方案和R-DHAP增加(1.1% vs 26.4%),R-CHOP或类似方案减少(64.5% vs 35.2%),R-苯达莫司汀增加(0% vs 12.1%),P < .001。
- ≤65岁患者Era 2的5年EFS为50.0% vs 34.3%(P = .010),5年OS为81.6% vs 68.8%(P = .017)。
- >65岁患者中,Era 2较Era 1的R-CHOP或类似方案减少(39.0% vs 14.3%),非标准系统治疗减少(36.6% vs 13.0%),R-苯达莫司汀增加(0% vs 49.4%)。
- >65岁患者Era 2的5年EFS为37.5% vs 25.4%(P = .051)。
- >65岁患者中,从R-CHOP或类似方案转向R-苯达莫司汀与EFS改善相关(5年EFS 44.6% vs 25.0%,P = .008)。
临床怎么用
- 真实世界证据提示MCL一线治疗从R-CHOP/R-Hyper-CVAD向R-苯达莫司汀、Nordic方案及R-DHAP演变可能与生存改善相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because there have been a dvances in frontline treatment for mantle cell lymphoma (MCL) over the last 2 decades, we sought to characterize the changes in frontline treatment patterns and their association with outcomes. Patients with newly diagnosed MCL from September 2002 through June 2015 were enrolled in a prospective cohort study, and clinical characteristics, treatment, and clinical outcomes were compared between patients diagnosed from 2002 to 2009 (Era 1) compared with 2010 to 2015 (Era 2). Patient age, sex, and simplified MCL International Prognostic Index (sMIPI) score were similar between the 2 groups. In patients age 65 years or younger, there was less use of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (R-Hyper-CVAD) (16.1% vs 8.8%) but more use of rituximab plus maximum-strength cyclophosphamide, doxorubicin, vincristine, and prednisone (R-maxi-CHOP) alternating with rituximab plus high-dose cytarabine (R-HiDAC), also known as the Nordic regimen, and R-CHOP alternating with rituximab plus dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) (1.1% vs 26.4%) and less use of R-CHOP or R-CHOP-like regimens (64.5% vs 35.2%) but more use of R-bendamustine (0% vs 12.1%) in Era 2 (P < .001). These changes were associated with improved event-free survival (EFS; 5-year EFS, 34.3% vs 50.0%; P = .010) and overall survival (OS; 5-year OS, 68.8% vs 81.6%; P = .017) in Era 2. In patients older than age 65 years, there was less use of R-CHOP or R-CHOP-like therapy (39.0% vs 14.3%) and nonstandard systemic therapy (36.6% vs 13.0%) but more use of R-bendamustine (0% vs 49.4%). These changes were associated with a trend for improved EFS (5-year EFS, 25.4% vs 37.5%; P = .051) in Era 2. The shift from R-CHOP or R-CHOP-like regimens to R-bendamustine was associated with improved EFS (5-year EFS, 25.0% vs 44.6%; P = .008) in Era 2. Results from this prospective cohort study provide critical real-world evidence for improved outcomes with evolving frontline patterns of care in patients with MCL.
引用
- Castellino A, Wang Y, Larson MC, et al. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Adv. 2022. PMID: 34662895. doi:10.1182/bloodadvances.2021005715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。